$18.20
0.66% yesterday
Nasdaq, Jun 27, 10:01 pm CET
ISIN
US82835W1080
Symbol
SPRY
Sector
Industry

Silverback Therapeutics Stock price

$18.20
+3.58 24.49% 1M
+7.41 68.67% 6M
+7.65 72.51% YTD
+10.15 126.09% 1Y
+13.76 309.91% 3Y
-2.80 13.33% 5Y
-2.80 13.33% 10Y
-2.80 13.33% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
+0.12 0.66%
ISIN
US82835W1080
Symbol
SPRY
Sector
Industry

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$1.5b
Net debt
$-275.7m
Cash
$275.7m
Shares outstanding
98.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
18.40 | 20.95
EV/Sales
15.57 | 17.72
EV/FCF
negative
P/B
7.80
Financial Health
Equity Ratio
73.13%
Return on Equity
3.11%
ROCE
-9.03%
ROIC
-
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$97.1m | $85.3m
EBITDA
$-26.7m | $-150.2m
EBIT
$-27.1m
Net Income
$-15.7m | $-147.5m
Free Cash Flow
$-21.1m
Growth (TTM | estimate)
Revenue
971,100.00% | -4.28%
EBITDA
56.85% | -4,941.47%
EBIT
56.34%
Net Income
68.51% | -1,943.38%
Free Cash Flow
60.72%
Margin (TTM | estimate)
Gross
97.35%
EBITDA
-27.51% | -176.06%
EBIT
-27.87%
Net
-16.11% | -172.82%
Free Cash Flow
-21.68%
More
EPS
$-0.15
FCF per Share
$-0.21
Short interest
27.61%
Employees
26.00
Rev per Employee
$3.43m
Show more

Is Silverback Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Silverback Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Silverback Therapeutics forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Silverback Therapeutics forecast:

Buy
92%
Hold
8%

Financial data from Silverback Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
97 97
971,100% 971,100%
100%
- Direct Costs 2.07 2.07
-
2%
95 95
-
97%
- Selling and Administrative Expenses 105 105
143% 143%
108%
- Research and Development Expense 17 17
9% 9%
18%
-27 -27
57% 57%
-28%
- Depreciation and Amortization 0.35 0.35
483% 483%
0%
EBIT (Operating Income) EBIT -27 -27
56% 56%
-28%
Net Profit -16 -16
69% 69%
-16%

In millions USD.

Don't miss a Thing! We will send you all news about Silverback Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Silverback Therapeutics Stock News

Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in pres...
Neutral
Seeking Alpha
about one month ago
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Justin Chakma - CBO Richard Lowenthal - Co-Founder, President and CEO Eric Karas - CCO Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Josh Schimmer - Cantor Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Andreas Argyrides -...
Neutral
GlobeNewsWire
about one month ago
$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, n...
More Silverback Therapeutics News

Company Profile

Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson on January 4, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Richard Lowenthal
Employees 26
Founded 2015
Website ars-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today